SYMPATHETIC PARAGANGLIOMA: A SINGLE-CENTER EXPERIENCE FROM WESTERN INDIA.

OBJECTIVE Most of the Indian studies on pheochromocytoma/paraganglioma (PCC/PGL) have focused on PCC, and there is a paucity of information regarding sympathetic paraganglioma (sPGL). Here, we describe the clinical, biochemical, and imaging features of sPGL compared with PCC. METHODS This retrospective study included 75 patients with sPGL and 150 patients with PCC. Diagnosis of PCC/PGL was based on surgical histopathology, and if histopathology was not available, on biochemistry and/or radiology. RESULTS sPGL was more frequently detected incidentally ( P = .03), normetanephrine-secreting ( P<.01), and metastatic compared with PCC ( P≤.01). sPGL was most commonly located in the organ of Zuckerkandl (OOZ) (49%) and infradiaphragmatic area above the OOZ (27%). Patients with mediastinal sPGL were significantly older than those with sPGL in the OOZ ( P = .03). Primary tumors of metastatic sPGL were significantly larger than those without metastasis (7.8 ± 4 cm vs. 5.6 ± 3.2 cm; P = .004). Percentage arterial enhancement (PAE) >100% was seen in 98% of sPGLs. CONCLUSION Incidental presentation, normetanephrine-secreting phenotype, and metastatic disease were more frequent in patients with sPGL than those with PCC. sPGL arose most commonly in the OOZ. Tumor size is an independent predictor of malignancy among sPGL patients. PAE >100% is almost a universal finding in sPGL, and its absence is a sensitive parameter to differentiate sPGL from other abdominal masses. ABBREVIATIONS AP = arterial phase; CECT = contrast-enhanced computed tomography; CT = computed tomography; DP = delayed phase; EVP = early venous phase; FDG = fluorodeoxyglucose; fPFMN = fractionated plasma free metanephrine; HU = Hounsfield units; MIBG = metaiodobenzylguanidine; MRI = magnetic resonance imaging; OOZ = organ of Zuckerkandl; PAE = percentage arterial enhancement; PCC = pheochromocytoma; PET = positron emission tomography; PFNMN = plasma free normetanephrine; PGL = paraganglioma; PRRT = peptide receptor radionuclide therapy; PVE = percentage venous enhancement; sPGL = sympathetic paraganglioma; UP = unenhanced phase; VMA = vanillyl mandelic acid.

[1]  Kun Zhang,et al.  MR imaging features of benign retroperitoneal paragangliomas and schwannomas , 2018, BMC Neurology.

[2]  A. Tischler,et al.  Pathology and genetics of phaeochromocytoma and paraganglioma , 2018, Histopathology.

[3]  N. Shah,et al.  Genetic status determines 18F‐FDG uptake in pheochromocytoma/paraganglioma , 2017, Journal of medical imaging and radiation oncology.

[4]  W. Young,et al.  Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years , 2017, The Journal of clinical endocrinology and metabolism.

[5]  C. Leemans,et al.  The phenotype of SDHB germline mutation carriers: a nationwide study. , 2017, European journal of endocrinology.

[6]  N. Shah,et al.  Raynaud's Phenomenon: Revisiting a Rare Sign of Pheochromocytoma and Paraganglioma. , 2017, Urology.

[7]  L. Wyrwicz,et al.  GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  N. Shah,et al.  Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience , 2016, Endocrine connections.

[9]  S. Khare,et al.  Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma. , 2016, European journal of endocrinology.

[10]  Robert A. Smith,et al.  Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. , 2016, Critical reviews in oncology/hematology.

[11]  Shouhao Zhou,et al.  Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. , 2015, European journal of endocrinology.

[12]  M. Blake,et al.  Images of pheochromocytoma in adrenal glands. , 2015, Gland surgery.

[13]  B. Robinson,et al.  15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1–5 , 2015, Endocrine-related cancer.

[14]  Z. Hussein,et al.  Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma , 2015, Nuclear Medicine and Molecular Imaging.

[15]  S. Sakellariou,et al.  A ‘giant’ paraganglioma in the testis , 2014, Endocrinology, diabetes & metabolism case reports.

[16]  T. Fojo,et al.  The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study , 2014, BMC Cancer.

[17]  M. Hofmann,et al.  Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.

[18]  J. Carrasquillo,et al.  Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. , 2012, Journal of the National Cancer Institute.

[19]  K. Pacak,et al.  Hypertension in pheochromocytoma: characteristics and treatment. , 2011, Endocrinology and metabolism clinics of North America.

[20]  Conn Jm,et al.  Abdominal Paragangliomas: Analysis of Surgeon's Experience , 2011 .

[21]  Lei Feng,et al.  Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. , 2011, The Journal of clinical endocrinology and metabolism.

[22]  F. Beuschlein,et al.  Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. , 2009, European journal of endocrinology.

[23]  J. Carrasquillo,et al.  Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. , 2009, The Journal of clinical endocrinology and metabolism.

[24]  T. Zelinka,et al.  Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. , 2008, Endocrine-related cancer.

[25]  Y. Wilson,et al.  Bowel perforation as a presenting feature of pheochromocytoma: case report and literature review. , 2005, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[26]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[27]  W. Young,et al.  Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. , 2001, The Journal of clinical endocrinology and metabolism.

[28]  C. Bradford,et al.  Sympathetic paraganglioma as an unusual cause of Horner's syndrome , 2001, Head & neck.

[29]  J. Varghese,et al.  MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. , 1997, Clinical radiology.